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OBJECTIVE — To determine whether maternal levels of follistatin-like-3 (FSTL3), an inhib-
itor of activin and myostatin involved in glucose homeostasis, are altered in the ﬁrst trimester of
pregnancies complicated by subsequent gestational diabetes mellitus (GDM).
RESEARCH DESIGN AND METHODS — This was a nested case-control study of
subjects enrolled in a prospective cohort of pregnant women with and without GDM (2
abnormal values on a 100-g glucose tolerance test at 28 weeks of gestation). We measured
FSTL3 levels in serum collected during the ﬁrst trimester of pregnancy. Logistic regression
analyses were used to determine the risk of GDM.
RESULTS — Women who developed GDM (n  37) had lower ﬁrst-trimester serum levels of
FSTL3 compared with women who did not (n  127) (median 10,789 [interquartile range
7,013–18,939] vs. 30,670 [18,370–55,484] pg/ml, P  0.001). When subjects were divided
into tertiles based on FSTL3 levels, women with the lowest levels demonstrated a marked
increase in risk for developing GDM in univariate (odds ratio 11.2 [95% CI 3.6–35.3]) and
multivariate (14.0 [4.1–47.9]) analyses. There was a signiﬁcant negative correlation between
ﬁrst-trimester FSTL3 levels and 28-week nonfasting glucose levels (r  0.30, P  0.001).
CONCLUSIONS — First-trimester FSTL3 levels are associated with glucose intolerance and
GDM later in pregnancy.
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G
estational diabetes mellitus (GDM)
afﬂicts 4% of pregnancies in the
U.S.andisassociatedwithunfavor-
able perinatal outcomes (1). Although
GDM is characterized by glucose intoler-
ance, -cell dysfunction, and insulin re-
sistance (1–3), the pathogenesis of GDM
is not well understood. The association
between GDM and insulin resistance
postpartumandsubsequenttype2diabe-
tes in up to 70% of mothers (1–4) has led
to the theory that GDM is simply the un-
masking of a chronic condition. However,
GDMresolves,atleasttemporarily,withthe
delivery of the infant and placenta, occurs
more often in twin pregnancy (5), and re-
curs only in 30–50% of subsequent preg-
nancies (6), suggesting that circulating
factors released by the placenta may be in-
volved,atleastpartially,initspathogenesis.
Pregnant women are typically
screenedforGDMat24–28weeksofges-
tation. Despite the fact that insulin sensi-
tivity increases in the ﬁrst trimester of
pregnancy, a recent study showed that
higher ﬁrst-trimester levels of fasting
blood glucose were linearly associated
withincreasedriskofGDM,cesareansec-
tion, and macrosomia (7), suggesting that
thepathophysiologicprocessthatleadsto
GDM is underway weeks to months be-
fore its diagnosis. Thus, it is possible that
factors linked with the pathogenesis of
this condition may be present in blood
samples well before the clinical diagnosis
of GDM. Treatment of GDM in late preg-
nancy improves some adverse perinatal
outcomes (8,9), but earlier detection of
GDMthroughbiomarkermeasurementin
the ﬁrst trimester of pregnancy may per-
mitmoretimeforinterventionandleadto
greater positive effects of treatment on
maternal and fetal outcomes.
Follistatin-like-3 (FSTL3, also re-
ferred to as FLRG), a follistatin homolog
that inhibits circulating members of the
transforming growth factor- subfamily
of proteins (10), is highly expressed by
the placenta (11). FSTL3 expression is in-
creased in placentas from pregnancies
complicated by intrauterine growth re-
striction (12). Outside of pregnancy,
FSTL3 may play a major role in glucose
homeostasis, as FSTL3-null mice are
characterized by pancreatic -cell hyper-
plasia, elevated insulin levels, increased
glucose tolerance, and upregulation of
hepaticgluconeogenesis(13).Furtherev-
idencesupportingaroleforFSTL3inglu-
cose homeostasis includes the biological
activities of activin A and myostatin,
which are antagonized by FSTL3. Activin
A promotes proliferation of -cells and
secretion of insulin (14,15); activin A lev-
els were found to be elevated in pregnan-
cies affected by GDM in previous studies
(16,17). In mouse models, the absence of
myostatin promotes insulin sensitivity
and protects against weight gain (18,19).
Although circulating levels of myostatin
during pregnancy have not been described,
myostatin is expressed by the human pla-
centa and was shown to increase glucose
uptake by placental explants (20).
Based on the connection of FSTL3 to
glucose homeostasis and the presence of
insulin resistance and -cell dysfunction
in GDM, as well as the high expression
levels of FSTL3 in the placentas of infants
with small-for-gestational-age fetuses
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gestational-age infants in GDM, we hy-
pothesized that circulating levels of
FSTL3 would be altered in pregnancies
complicated by GDM.
RESEARCH DESIGN AND
METHODS— We conducted a nest-
ed-case control study to determine
whether ﬁrst-trimester FSTL3 levels were
different in women who did and did not
develop subsequent GDM. The parent
study, the MGH Obstetrical Maternal
Study (MOMS), a prospective cohort
studyofpregnantmothers,wasdescribed
previously (21). MOMS subjects were re-
cruited from women receiving prenatal
care at Massachusetts General Hospital
and afﬁliated health centers between
1998 and 2005. Of eligible women, 70%
enrolled in the cohort at their ﬁrst prena-
tal visit. Blood samples were collected at
this time and stored at 80°C for future
analysis. Clinical information including
subject characteristics, glucose tolerance
test results, and birth outcomes was col-
lected from the obstetric electronic medical
record. All subjects gave written informed
consent, and the study protocol was ap-
proved by the Partners Human Research
Committee (institutional review board).
We excluded subjects with a history
of GDM in a previous pregnancy, those
with preeclampsia (systolic blood pres-
sure140mmHgordiastolicbloodpres-
sure 90 mmHg and proteinuria), those
with small-for-gestational-age infants
(10th percentile in birth weight for ges-
tational age), those with multiple gesta-
tions, and those found to have glucose
intolerance at 20 weeks of gestation, as
this may represent pregestational diabe-
tes. The standard of care at Massachusetts
General Hospital is to screen all pregnant
women at 24–28 weeks of gestation with
a 50-g, 1-h glucose challenge test (GCT).
Women with blood glucose 140 mg/dl
1 h after administration of the glucose
challenge undergo subsequent glucose
tolerance testing consisting of the admin-
istration of 100 g glucose after a 12-h fast
and the measurement of blood glucose
levels0,1,2,and3hafterglucoseadmin-
istration. GDM cases were deﬁned as
those women who had 2 abnormal val-
ues on glucose tolerance test (GTT) in ac-
cordance with American Diabetes
Association guidelines (1). Control subjects
were chosen randomly from women who
passedtheGCTand/orGTT.Weproceeded
with a 1:3 case subject–to–control subject
ratio based on previous studies of biomark-
ers in this population (21). We focused on
subjectsforwhomenoughserumwasavail-
able in the sample bank to perform FSTL3
measurements in duplicate.
Testing of serum samples was per-
formed using a human FSTL3 DuoSet
ELISA (DY1288; R&D Systems, Minne-
apolis, MN). Assays were run in dupli-
cate, and the operator was blinded to the
clinical data. A standard curve was gener-
ated using serial dilutions of recombinant
FSTL3 (1288-F3; R&D Systems) at con-
centrations ranging from 10 ng/ml to 100
pg/ml in Reagent Diluent (1% BSA/PBS,
DY995;R&DSystems).Allreactionswere
performed at room temperature. Plates
were coated overnight with primary
mouse antihuman FSTL3 antibody in 4
g/ml PBS (100 l/well). On the day of
the assay, each well was washed three
times with 400 l/well wash buffer
(0.05% Tween 20/PBS, WA126; R&D
Systems), using a Columbus Pro washer
(Tecan) and then blocked with 300
l/well Reagent Diluent for 1 h. Plates
were then washed three times with wash
buffer, and 100 l standard or sample
was added to each well. Plates were incu-
bated for2ho natable-top shaker and
washed three times as described above.
Then 400 ng/ml secondary biotinylated
mouse antihuman FSTL3 antibody (100
l/well)wasadded,andplateswereincu-
bated for2ho natable-top shaker. Plates
werewashedagainwithwashbufferthree
times, and streptavidin conjugated to
horseradish peroxidase (100 l/well) was
added for 20 min. Plates were washed
three times in wash buffer, and color re-
agent containing H2O2 and tetramethyl-
benzidine (100 l/well) was added
(DY993;R&DSystems).Plateswereincu-
bated for 20 min and stop solution (2 N
H2SO4,5 0l, DY994; R&DSystems) was
added to each well. Optical density was
measuredusingamicroplatereader(model
660;Bio-RadLaboratories).Opticaldensity
at550nmwassubtractedfromopticalden-
sity at 450 nm, and serum concentrations
were determined using a standard curve
generated by a quadratic plot of the stan-
dardsampleconcentrationsversusthemea-
sured optical density. The interassay
coefﬁcient of variation for this assay was
10.5%.
Subject characteristics and levels of
FSTL3 in case and control subjects were
comparedusingttests,Wilcoxontests,or

2testsasappropriate.Withinthecontrol
group, one-way ANOVA was performed
to determine whether FSTL3 levels dif-
fered in women who had failed the GCT
but passed the GTT. Subjects were di-
vided into tertiles based on FSTL3 levels,
and odds ratios for the development of
GDMwerecalculatedforeachtertile.Logis-
tic regression analysis with appropriate in-
dicator variables was performed to create
univariate and multivariate models for the
odds of developing GDM. Spearman corre-
lationsbetweenFSTL3levels,bloodglucose
levels after a 50-g glucose challenge, and
other subject characteristics were sought.
Statisticalanalyseswereperformedwiththe
use of SAS 9.0 (SAS Institute, Cary, NC).
RESULTS— Characteristics of the 37
subjects who developed GDM and the
Table 1—Characteristics of subjects with and without GDM at prenatal visit and delivery
GDM Control P*
n 37 127
First prenatal visit
Gestational age (weeks) 10.5  0.32 11.0  0.15 0.20
Age (years) 34.2  0.86 34.0  0.41 0.80
BMI (kg/m
2) 29.2  1.4 26.8  0.49 0.20
Systolic blood pressure (mmHg) 114  1.6 112  1.05 0.32
Diastolic blood pressure (mmHg) 72  1.4 70  0.73 0.09
% nulliparous 46 42 0.65
% Caucasian 65 81 0.04†
Delivery
Gestational age (weeks) 39.0  0.20 39.8  0.10 0.001†
Weight gain (lb) 22.3  1.9 27.5  1.3 0.005†
Birth weight (g) 3,491  91 3,538  43 0.62
Cesarean section (%) 30 28 0.80
Data are means  SEM or %. *P value reﬂects t test for normally distributed variables (age, gestational age,
and birth weight), Mann-Whitney-Wilcoxon test for nonnormally distributed variables (BMI, blood pres-
sure, and weight gain), and 
2 test for categorical variables (race, parity, and cesarean section). †Signiﬁcant
at P  0.05 level.
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ble 1. Subjects were similar in age and
parity and had similar blood pressures
measured at the ﬁrst prenatal visit. Gesta-
tional age at the time of blood collection
was similar in both groups. Subjects who
developed GDM had slightly greater BMI
compared with those who did not, but
this difference was not statistically sig-
niﬁcant. There was a greater percentage
of Caucasians in the control group than
in the GDM group. Women with GDM
delivered earlier in gestation than con-
trol women, and women with GDM
gainedlessweightbetweentheﬁrstvisit
and delivery. Infant birth weight and
percentageofwomenundergoingcesar-
ean section did not differ between the
groups.
First-trimester FSTL3 levels were
lower in subjects who developed GDM
than in control subjects (median 10,789
[interquartile range 7,013–18,939] vs.
30,670 [18,370–55,484] pg/ml, P 
0.001) (Fig. 1). Average FSTL3 levels in
subjects who failed the GCT but passed
the GTT was 27,313 [20,609–54,169]
pg/ml, lower but not signiﬁcantly differ-
ent from FSTL3 levels in women who
passed the GCT (31,066 [18,039–
59,407] pg/ml, P  0.614) and signiﬁ-
cantly greater than those who went on to
develop GDM (P  0.001). When sub-
jects were divided into tertiles based on
FSTL3 levels, women in the ﬁrst tertile
had an 11.2-fold risk of developing GDM
compared with women in the third tertile
(Fig. 2). This odds ratio increased to 14.0
after adjustment for gestational age at
blood collection, maternal age, race,
BMI, blood pressure, and parity. In the
multivariate logistic regression model,
only FSTL3 tertile and nonwhite race
were signiﬁcant independent predictors
of GDM.
FSTL3 was not correlated with gesta-
tional age at blood collection (P  0.44),
BMI (P  0.29), systolic blood pressure
(P  0.87), diastolic blood pressure (P 
0.96), nonwhite race (P  0.40), or ma-
ternal age (P  0.71). There was no dif-
ference between levels of FSTL3 in white
and nonwhite women (P  0.90), be-
tween nulliparas and multiparas (0.70),
or between women with different smok-
inghistories(P0.80).Bloodglucose1h
aftera50-gglucoseload(GCTresult)was
inverselycorrelatedwithFSTL3level(r
0.30, P  0.001) (Fig. 3) and positively
correlated with BMI (r  0.18, P  0.03)
andnonwhiterace(r0.23,P0.003).
In a multivariate linear regression model,
only FSTL3 and nonwhite race indepen-
dently predicted GCT result.
CONCLUSIONS — In this nested
case-control study, we showed that low
FSTL3 levels in the ﬁrst trimester are as-
sociated with the development of glucose
intolerance and GDM later in pregnancy.
When subjects were divided into tertiles
based on FSTL3 levels, women with the
lowestlevelsdemonstratedamarkedlyel-
evated risk compared with women with
the highest levels. This estimate of risk
wasfurtherincreasedafteradjustmentfor
age, BMI, nonwhite race, blood pressure,
and multiparity, which are known risk
factors for GDM (22). Levels of FSTL3
were inversely correlated with levels of
blood glucose during a 50-g GCT. These
dataareconsistentwith,butdonotprove,
involvement of FSTL3 in GDM patho-
physiology.Theassociationbetweenﬁrst-
trimester FSTL3 levels and subsequent
GDM may allow FSTL3 to be tested as a
candidate biomarker for estimation of
GDM risk early in pregnancy.
We expect that our sample is repre-
sentative of the pregnant population
treated at a large New England hospital,
with the exception that no subject had a
previous history of GDM. Of the subjects,
23% were ethnic/racial minorities. Sub-
jects with and without GDM were similar
with the exception of race, gestational age
at delivery, and weight gain during preg-
nancy.Nonwhiteraceisaknownriskfac-
tor for GDM (22); this may explain the
difference in racial makeup of the case
and control groups. Women with GDM
are followed closely for fetal growth and
delivery is targeted if there is concern for
macrosomia (1). This probably accounts
fortheyoungergestationalageatdelivery,
lower weight gain, and similar birth
weights in the GDM group. FSTL3 levels
were not correlated with BMI, parity, ma-
ternalage,nonwhiterace,orsmokinghis-
tory, clinical factors known to be
associatedwithGDM(22).Inoursample,
BMI, parity, maternal age, and smoking
history were not signiﬁcantly associated
with a higher risk of GDM, implying that
our study may have been underpowered
to detect these known relationships and
any relationship between these factors
and FSTL3. In contrast, FSTL3 level and
nonwhite race predicted GDM indepen-
dently, implying that FSTL3 levels in
Figure 1—First-trimester FSTL3 levels in women who did and did not develop GDM. FSTL3
levels were measured in serum collected from women with GDM and control subjects at the ﬁrst
prenatal obstetric visit. FSTL3 levels were signiﬁcantly lower in women who developed GDM (P
 0.001). Box plots depict the median (horizontal line in each box), the 25th percentile (bottom
of each box), and the 75th percentile (top of each box). Box whiskers extend to the highest/lowest
nonoutliervalue.Outliersweredeﬁnedaslyinggreaterthanthreeinterquartilerangesoutsidethe
25th or 75th percentile. Scatter plot overlay depicts levels of FSTL3 in individual subjects.
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explain the reason for their known ele-
vated risk for GDM.
Because the placenta expresses high
levels of FSTL3, we suspect it to be the
major source of FSTL3 in the maternal
serum, but we did not test this hypothe-
sis. FSTL3 is also expressed at a moderate
level by the pancreas and other adult tis-
sues. Given the pancreatic hypertrophy
and hypersecretion that occur during
pregnancy, we cannot rule out the pan-
creas or other maternal tissues as a source
of circulating FSTL3.
Although we did not test the validity
of potential pathophysiological mecha-
nisms operating in GDM, our ﬁnding of
low FSTL3 levels in pregnancies compli-
cated by GDM suggests that FSTL3 may
beinvolvedinglucosemetabolismduring
pregnancy. The third trimester of normal
pregnancy is characterized by insulin re-
sistance, which is matched by pancreatic
-cell hyperplasia and increased insulin
secretion (3), resulting in normal glucose
tolerance. The signals leading to upregu-
lation of pancreatic -cell performance
during pregnancy are unknown. How-
ever, the action of activin A on pancreatic
-cells (14,15), our ﬁnding of low FSTL3
levels in the serum of women with GDM,
and the previous reports of elevated ac-
tivin A levels in pregnancies affected by
GDM (16,17) underscore a possible role
for activin A in the promotion of islet cell
hyperplasia and increased insulin secre-
tion during pregnancy.
Figure 3—Relationship between ﬁrst trimester FSTL3 and GCT result. Glucose challenge test
(GDM screening) was performed at 24–28 weeks of gestation. A 50-g glucose load was adminis-
tered orally, and blood glucose was measured after 1 h. r  0.30, P  0.001 (Spearman
correlation). Red markers represent GDM case subjects; blue markers represent control subjects.
Figure 2—Odds of developing GDM by ﬁrst-trimester FSTL3 tertile. Subjects were divided into tertiles based on the ﬁrst-trimester FSTL3 level.
Univariate (dark blue) and multivariate (light blue) logistic regression analyses were used to determine odds ratios for the development of GDM in
eachtertile.Themultivariatelogisticregressionmodelincludesadjustmentforage,gestationalage,diastolicbloodpressure,BMI,nonwhiterace,and
multiparity. *Signiﬁcantly different from the reference tertile at the P  0.05 level.
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nancy may convey an adaptive advantage
to the fetus in terms of energy acquisition
and is thus presumed to be caused by a
combination of placental hormones in-
cluding human placental lactogen; how-
ever, most studies have not found a
correlation between levels of previously
studied placental hormones and insulin
resistance in pregnant women (23). Be-
cause GDM is characterized by insulin re-
sistance in excess of normal pregnancy
(1–3), GDM may represent a maternal-
fetal conﬂict over energy resources, and
yet unexplored factors released by the
placenta may be involved in its pathogen-
esis. Myostatin, whose absence is known
to promote insulin sensitivity and protect
againstweightgain(18),isreleasedbythe
placenta during pregnancy in unknown
amounts (20). Thus, myostatin may be a
candidate protein for contribution to the
insulin resistance of pregnancy and/or
GDM. We speculate that low levels of
FSTL3 may be involved in GDM physiol-
ogy by either leading to disinhibition of
myostatin, promoting excessive insulin
resistance, or leading to disinhibition of
activin A, promoting compensatory insulin
secretion in the setting of hyperglycemia.
FSTL3 levels were inversely corre-
lated with glucose challenge screening
test results, underscoring the possible
clinical utility of FSTL3 measurement
early in pregnancy. Of note, our study
does not indicate how FSTL3 levels com-
pare in utility to other screening tests for
GDM. With the GTT as a gold standard,
one large study showed that the GCT had
asensitivityofjust73%(24).Itispossible
that women with low FSTL3 levels who
passedtheGCTmighthavehadanabnor-
mal GTT if such testing had been per-
formed. Consistent with this possibility,
our data show that women who failed the
GCT but passed the GTT had FSTL3 lev-
els similar to those of women who passed
the GCT. Measurement of FSTL3 in a
sample in which all subjects undergo glu-
cose tolerance testing would provide a
better estimation of the sensitivity and
speciﬁcity of FSTL3 testing. In our sam-
ple, FSTL3 testing with a cutoff point of
50,000 pg/ml could have eliminated the
GCT for 29% of women, while still recog-
nizing 95% of women with GDM identi-
ﬁed by routine screening. Given current
U.S. practices of universal screening and
the controversy surrounding selec-
tive screening based on risk factors (25),
this ﬁnding has potential cost-saving
implications.
Strengths of our study include pro-
spective data collection and the large
amount of clinical data available to us
throughtheMOMSstudy.Limitationsin-
clude the lack of longitudinal data on
FSTL3 levels and the lack of glucose tol-
erance testing in every participant. Mea-
surement of FSTL3 levels throughout
pregnancy would provide a context in
which to interpret FSTL3 levels. A longi-
tudinal study of FSTL3 levels could also
provide information as to whether FSTL3
is a marker of insulin sensitivity during
pregnancy and whether FSTL3 levels in-
crease with increasing placental mass. Al-
though our data provide evidence of an
association between low ﬁrst-trimester
FSTL3 levels and GDM, the involvement
ofFSTL3 in any causal or compensatory
pathway has not been proven. Investi-
gation of the role of FSTL3 in glucose
homeostasis may provide insights into
GDM pathogenesis and should be un-
dertaken using animal models. Ulti-
mately, measurement of FSTL3 level
maybeameanstodistinguishwomenat
high and low risk for GDM early in
pregnancy, but clinical trials using im-
proved automated assays will be neces-
sary before implementation of any
future clinical laboratory test based on
the measurement of FSTL3.
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